What Cardizem Treats: Main Uses and Benefits

Cardizem (diltiazem hydrochloride) is a medication that belongs to a class of drugs called calcium channel blockers. Its primary therapeutic uses are focused on managing cardiovascular conditions.

The medication is commonly used across conditions presenting with acute episodes, including the symptomatic management of hypertension and addressing periods of heightened symptoms associated with chronic stable angina or angina due to coronary artery spasm. It may be part of symptomatic management during phases when symptoms become more noticeable and is considered relevant for conditions involving episodic or fluctuating manifestations.

The specific condition categories for which Cardizem is commonly used include hypertension (high blood pressure) and the management of symptom clusters associated with different types of angina (chest pain). It supports patients during episodes of heightened discomfort and assists with managing symptoms related to heightened physiological activity in contexts involving systemic burden. As a patient benefit, it helps to ease the overall symptom burden and provides supportive relief when symptoms interfere with routine activities.

“Cardizem contributes to improved comfort during periods of heightened symptoms and offers symptomatic relief that helps patients cope more steadily with physical discomfort.”

---

Quick Fact: Relief for Physical Discomfort

Overall, Cardizem supports patients during episodes of heightened discomfort and assists with managing symptoms related to heightened physiological activity in contexts involving systemic burden.

Cardizem (diltiazem hydrochloride) is an adult-use medication and its eligibility is strictly defined by regulatory documents based on existing cardiac and physiological conditions.

Populations that Must Not Use Cardizem

The medicine is contraindicated and must not be used in the following populations:

• Patients with Sick Sinus Syndrome or second- or third-degree AV block, unless a functioning ventricular pacemaker is present.
• Patients with hypotension (systolic blood pressure less than 90 mm Hg).
• Patients with known hypersensitivity to the drug.
• Patients with acute myocardial infarction and pulmonary congestion.
• Patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract (e.g., Wolff-Parkinson-White syndrome).

Populations Requiring Special Consideration

Population/Condition	Regulatory Status (Excerpt)
Pediatric Use	Safety and effectiveness have not been established; appropriate studies have not been performed.
Heart Failure	Use with caution due to limited experience and potential to worsen impaired ventricular function.
Hepatic/Renal Impairment	Use with caution and monitoring is recommended, as the drug's effects may be prolonged.
Pregnancy/Lactation	Diltiazem is excreted into human milk; potential risk to the infant must be weighed against the drug's importance to the mother.

Eligibility for Cardizem is centered on the absence of these major conduction and hemodynamic contraindications, requiring careful assessment for existing organ impairment or cardiac dysfunction.

Interactions with other medicines and products for Cardizem (Diltiazem)

Cardizem's interaction profile is documented in regulatory labeling and involves both effects on heart function and metabolic pathways. It is essential to understand these documented interactions before co-administering other substances.

---

Pharmacodynamic and Cardiac Interactions

Co-administration with other agents that slow heart rate or suppress cardiac function (e.g., Beta-blockers or Digoxin) requires caution due to the risk of additive effects on cardiac conduction, such as severe bradycardia or AV block. This additive effect is a primary concern noted in official documentation.

Metabolic and Exposure Interactions

Cardizem is a documented inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme and the P-glycoprotein (P-gp) transporter. Due to this inhibitory action, the plasma concentration (exposure) of many co-administered drugs that are substrates of these systems can significantly increase.

Clinically significant increases in drug levels are documented for:

• Statins (e.g., Simvastatin, Lovastatin)
• Benzodiazepines (e.g., Midazolam, Triazolam)
• Immunosuppressants (e.g., Cyclosporine)

Food and Substance Interactions

Official labeling notes that grapefruit juice may increase diltiazem plasma concentrations. Additionally, some formulations may carry warnings regarding the co-administration of alcohol, as it may affect the rate of drug release and systemic exposure. Caution is also advised when using certain herbal products (e.g., St. John's Wort) due to their potential to alter drug metabolism.

Contraindication Constraints

Specific contraindicated combinations are listed, including agents such as Ivabradine and Lomitapide, due to the potential for serious adverse effects when combined with diltiazem.

Diltiazem acts by blocking L-type voltage-gated calcium channels ( Cav1.2) in the cardiovascular system. This inhibition restricts the influx of calcium ions ( Ca^2+), which mediate muscle contraction and electrical signaling. The mechanism's inhibitory effect is amplified under conditions of high electrical activity, a property known as use-dependence.

The action is divided between the heart's electrical system and its muscle cells. In the heart's conduction system, Diltiazem primarily targets the Cav1.2 channels located in the Atrioventricular (AV) node. By slowing the critical Ca^2+-dependent current through this node, Diltiazem modulates the speed of electrical impulse transmission, resulting in negative chronotropy (slowing the heart rate) and modifying impulse propagation.

Simultaneously, the blockade impacts vascular smooth muscle cells (VSMCs) and cardiac myocytes. Restricting the calcium available to VSMCs leads to their relaxation, causing vasodilation and a reduction in systemic arterial resistance. In cardiac myocytes, the reduction of calcium results in negative inotropy (decreased contractile force). These mechanical and electrical actions combine to result in a reduced cardiac energy expenditure and a decrease in myocardial oxygen consumption ( MVO2).

How to use Cardizem: Official Administration Guidelines

Cardizem (diltiazem hydrochloride) is administered via the Oral route (tablets or capsules) for routine therapy or via Intravenous (IV) injection/infusion for the temporary control of rapid heart rate.

Oral Administration Protocol

Formulation	Frequency & Timing	Dosing & Preparation
Immediate-Release Tablets	Four times a day (before meals and at bedtime)	Initial adult dose is typically 30 mg four times daily. Tablets (30 mg to 120 mg) may be swallowed whole, crushed, or chewed, but the 30 mg tablet must not be split.
Extended-Release (ER) Forms	Once daily (at approximately the same time)	Initial dose ranges from 120 mg to 240 mg once daily. Swallow whole; do not chew or crush the capsule or tablet. Some specific ER capsules may be opened and sprinkled onto a spoonful of applesauce for immediate swallowing without chewing.

Intravenous Administration Protocol

IV administration is for institutional use only, beginning with a bolus injection followed by an infusion. The initial dose is 0.25 mg/kg actual body weight administered over 2 minutes. If the response is inadequate, a second dose of 0.35 mg/kg may be given after 15 minutes. This is immediately followed by a continuous infusion, typically starting at 10 mg/hour (adjusting up to 15 mg/hour as needed), generally not exceeding 24 hours.

General Procedural Rules

• Missed Dose: If a dose is missed, take it as soon as possible. If it is almost time for the next scheduled dose, skip the missed dose and return to the regular schedule. Do not double doses.
• Age-Specific Use: Safety and efficacy in the pediatric population (children/adolescents) have not been established. Dose reduction may be necessary for elderly patients due to potentially lower requirements.

Research Evidence Overview for Cardizem (Diltiazem)

This section summarizes the official research that has been conducted in relation to Cardizem, focusing on the types of studies available and the specific outcomes that researchers have monitored. The evidence base includes findings from Randomized Controlled Trials (RCTs) and systematic reviews, which are referenced by regulatory bodies for context.

---

Evidence for the Management of High Blood Pressure

Research was studied in comparative outcome trials and meta-analyses. These examined outcomes related to systemic imbalance, such as changes in systolic and diastolic blood pressure and the occurrence of major cardiovascular events (e.g., stroke). Findings describe patterns observed in diverse patient groups, including many older adults. Certain early aggregated data show some heterogeneity (variability), and long-term effects are not fully established when considering specific dosage timing.

---

Evidence for Symptom Management in Angina

Research has examined Diltiazem in stable angina and angina due to coronary artery spasm using placebo-controlled, short-term randomized trials. Studies recorded measurements related to angina episode frequency, the usage of rescue medications, and objective functional measures like the total duration of exercise achieved. Research generally focuses on symptomatic and functional endpoints rather than long-term outcomes. The initial key studies for coronary artery spasm were conducted in populations where sample sizes were modest.

---

Evidence for Rate Control in Atrial Arrhythmias

Diltiazem was evaluated in acute settings, such as atrial fibrillation, using intravenous (IV) solutions. These studies monitored the ability to achieve ventricular rate control (slowing the heart rate) within minutes to hours. Data show patterns that limit the applicability of evidence for patients with certain types of existing heart conditions. Comparative evidence is lacking for large-scale, long-term randomized trials that compare different chronic rate control strategies.

---

Evidence Landscape and Research Gaps

Research has explored long-term outcomes most extensively in the context of high blood pressure, where follow-up durations were assessed over multiple years. For other uses, follow-up durations were limited. Data for certain groups, such as pediatric patients, remain insufficient. For angina management, there is limited information on long-term prognostic outcomes related to survival. Research highlights that certain early aggregated data show some heterogeneity, indicating that results apply only to the specific conditions under which they were conducted.

Common questions about Cardizem (FAQ)

Q: What is Cardizem (Diltiazem) used for?

A: Cardizem (diltiazem hydrochloride) is a medication that has been authorized for use in the management of specific cardiovascular conditions. These indications typically include the treatment of hypertension (high blood pressure) and chronic stable angina (chest pain).

Q: How does Cardizem work?

A: Studies indicate that diltiazem acts as a calcium channel blocker. The drug influences the movement of calcium ions into cardiac muscle and vascular smooth muscle cells. The observed effects include a reduction in heart rate and a decrease in blood pressure.

Q: What are the potential side effects of Cardizem?

A: Clinical trials and post-marketing surveillance have reported various side effects associated with diltiazem use. Common effects observed may include: headache, dizziness, edema (swelling, particularly in the ankles or feet), and nausea.

Less common, but potentially serious effects have been reported, such as abnormally slow heart rates (bradycardia), changes in heart rhythm or conduction, and manifestations of liver injury. It is important to discuss all known side effects with a healthcare professional.

Q: Is Cardizem safe to take with other heart medications like beta-blockers or digoxin?

A: Concomitant use of Cardizem with other medications that affect heart rate and conduction, such as beta-blockers or digoxin, requires careful medical supervision.

Evidence suggests that combining these agents may lead to additive effects on cardiac conduction, which could potentially result in abnormally slow heart rates or other rhythm disturbances. A healthcare provider is best suited to determine if a combination therapy is appropriate.

Q: What if I have a history of heart failure or impaired liver/kidney function?

A: Cardizem should be used with caution in individuals with certain pre-existing conditions.

• Heart failure: There have been reports of worsening heart failure in patients with impaired ventricular function.
• Liver or kidney impairment: Because the drug is extensively metabolized by the liver and excreted by the kidneys, caution and regular monitoring of these organ functions are warranted in patients with existing impairment.

These conditions may affect how the body processes the medication. A complete medical history is essential for appropriate assessment.

Q: Is Cardizem contraindicated for any conditions?

A: Cardizem is generally contraindicated (should not be used) in patients with certain conditions, including:

• Sick sinus syndrome (except in the presence of a functioning ventricular pacemaker).
• Second- or third-degree AV block (except in the presence of a functioning ventricular pacemaker).
• Hypotension (very low blood pressure).

It is critical that a patient review all existing medical conditions with a prescribing healthcare professional.

How to Store and Dispose of Cardizem (Diltiazem Hydrochloride)

Official regulatory guidelines define strict conditions for storing and disposing of Cardizem to maintain its stability and ensure safety.

---

Storage Requirements

Cardizem must be stored at Controlled Room Temperature (20 C to 25 C), with permitted excursions up to 30 C. The medication requires protection from excessive moisture and heat. It must be kept in its original, tightly closed, light-resistant container and stored out of the reach of children.

---

Disposal Instructions

Unused or expired Cardizem should be disposed of according to local regulations or through a community drug take-back program. It is essential not to flush this medication down the toilet or pour it into a drain to prevent environmental contamination.